AZD 9773

Drug Profile

AZD 9773

Alternative Names: AZD9773; CytoFab

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Protherics
  • Developer AstraZeneca; BTG; Protherics
  • Class Polyclonal antibodies
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cardiovascular disorders; Coronary disorders; Crohn's disease; Graft-versus-host disease; Jarisch-Herxheimer reaction; Malaria; Septic shock; Transplant rejection

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 08 Aug 2012 Discontinued - Phase-II for Septic shock in Australia (IV)
  • 08 Aug 2012 Discontinued - Phase-II for Septic shock in Belgium (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top